CG Oncology

Results of Cretostimogene Grenadenorepvec Combined With Pembrolizumab in BCG-Unresponsive NMIBC

The page discusses bladder cancer’s unmet medical needs and the potential of a dual-acting treatment mechanism.

Interact with the full pipeline of ongoing cretostimogene clinical trials for non-muscle invasive bladder cancer (NMIBC).

A renewed push into early bladder cancer

BOND-003 A phase 3 study of cretostimogene grenadenorepvec in patients with NMIBC that is unresponsive to BCG (pdf)

Cretostimogene grenadenorepvec, a conditionally replicating granulocyte macrophage colony-stimulating factor–armed oncolytic adenovirus for the treatment of bladder cancer – PubMed (nih.gov)

This phase 1 trial investigates cretostimogene grenadenorepvec, a GM-CSF-expressing oncolytic adenovirus, for treating nonmuscle-invasive bladder cancer.

BOND-003, Phase 3 cretostimogene grenadenorepvec monotherapy pivotal trial in BCG-unresponsive NMIBC (pdf)

Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial

FDA Grants Fast Track, Breakthrough Therapy Designations to Cretostimogene Grenadenorepvec for NMIBC

Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer

The CG Oncology Executive Leadership team has personalconnections to bladder cancer and is focused on bringing forwardlife-changing therapies.

CG Oncology provides contact information for its medical affairs, media, and investment relations teams.

CG Oncology is a late-stage pharmaceutical company that is passionate about developing and delivering bladder-sparing immunotherapies.

CG Oncology collects contact details, such as name and email, when users communicate with them.